NDA accepted for BioXcel schizophrenia/bipolar drug
New Haven’s BioXcel Therapeutics has taken a major step forward in its push to bring its first commercial drug to the marketplace. The FDA recently accepted...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
New Haven’s BioXcel Therapeutics has taken a major step forward in its push to bring its first commercial drug to the marketplace. The FDA recently accepted...
Woodbridge-based green chemistry company P2 Science has launched its 12th green chemistry-based product to be commercialized since April 2020: Herbenone. Herbenone is a new herbal...
AdventHealth and Sema4 have announced a wide-ranging collaboration that builds upon the current AdventHealth Genomics and Personalized Health Program to provide new research insights and...
In this interview, Aman shares how his early passion for theatre and drama has translated into a business strength and charts his personal career journey from India to Connecticut. In his...
Neag School assistant professor of learning sciences, Ido Davidesco, has received a $1.4 million grant from the National Science Foundation to develop a month-long computational...
The question of whether groups of organisms respond to evolution as a collective — through so called multi-level selection — has been studied for decades,...
Alexion Pharmaceuticals will keep its New Haven team in place following its merger with drug giant AstraZeneca — at least through the end of 2021,...
Cybrexa Therapeutics has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer. “With our lead therapeutic candidate, CBX-12, currently in its Phase 1...
A gene therapy biotech helmed by an Alexion Pharmaceuticals co-founder has raised $40 million to develop a pipeline of drugs based on technology it licensed...
CytoVeris reports that Henry Couture has joined the company as Director of Quality. Mr. Couture has an extensive background with over 20 years of experience leading...